Efficacy and safety of colchicine for the treatment of
osteoarthritis: a systematic review and meta-analysis of
intervention trials

J 2023

Efficacy and safety of colchicine for the treatment of osteoarthritis: a systematic review and meta-analysis of intervention trials

SINGH, Ambrish, Pablo MOLINA-GARCIA, Mohammad Salman HUSSAIN, Alok PAUL, Siddharth Kumar DAS et. al.

Základní údaje

Originální název

Efficacy and safety of colchicine for the treatment of osteoarthritis: a systematic review and meta-analysis of intervention trials

Autoři

SINGH, Ambrish, Pablo MOLINA-GARCIA, Mohammad Salman HUSSAIN (356 Indie, domácí), Alok PAUL, Siddharth Kumar DAS, Leung YING-YING, Catherine L HILL, Debashish DANDA, Jonathan SAMUELS a Benny ANTONY (garant)

Vydání

Clinical Rheumatology, LONDON, SPRINGER LONDON LTD, 2023, 0770-3198

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30226 Rheumatology

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 3.400 v roce 2022

Kód RIV

RIV/00216224:14110/23:00130039

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1007/s10067-022-06402-w

UT WoS

000866341500001

Klíčová slova anglicky

Calcium pyrophosphate; Chondrocalcinosis; Colchicine; Osteoarthritis; Osteoarthritis knee

Štítky

14119612, 14119613, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 26. 1. 2024 10:15, Mgr. Tereza Miškechová

Anotace

V originále

Objective Colchicine, an approved treatment for gout, has been trialed in many diseases including osteoarthritis (OA) due to its anti-inflammatory effects. However, its efficacy and safety remain unclear in OA. This systematic review and meta-analysis evaluated the efficacy and safety of colchicine for the treatment of OA. Methods PubMed, Web of Science, Scopus, and Cochrane Central were searched from inception through September 2022. Two reviewers independently screened for randomized controlled trials (RCTs) comparing colchicine with placebo or other active comparators for the treatment of OA (knee, hand, or hip OA), extracted data, and performed Cochrane risk of bias assessments. Result Nine RCTs for the knee OA and one for the hand OA were identified, consisting of 847 patients (429 in colchicine arms, 409 in control arms). The studies were conducted between 2002 and 2021 with follow-up periods ranging from 2 to 12 months, in India, Iran, Turkey, Australia, Singapore, and Iraq. Moderate-quality evidence showed no clinically important pain reduction with colchicine compared to control (standardized mean difference [SMD], 0.17; 95% confidence interval [CI], − 0.55, 0.22). Moderate-quality evidence showed no improvement in function with colchicine compared to control in knee OA patients (SMD, − 0.37; 95% CI, − 0.87, 0.13). Colchicine showed an acceptable safety profile with AEs/SAEs comparable to control. Conclusion Current evidence does not suggest a benefit of colchicine in reducing pain and improving physical function in the overall cohort of hand/knee OA patients. Future trials should focus on the subgroups of OA patients with local or systemic inflammation and/or mineralization who might benefit from colchicine.

Návaznosti

EF18_053/0016952, projekt VaV

Název: Postdoc2MUNI

Citovat

SINGH, Ambrish, Pablo MOLINA-GARCIA, Mohammad Salman HUSSAIN, Alok PAUL, Siddharth Kumar DAS, Leung YING-YING, Catherine L HILL, Debashish DANDA, Jonathan SAMUELS a Benny ANTONY. Efficacy and safety of colchicine for the treatment of osteoarthritis: a systematic review and meta-analysis of intervention trials. Clinical Rheumatology. LONDON: SPRINGER LONDON LTD, 2023, roč. 42, č. 3, s. 889-902. ISSN 0770-3198. Dostupné z: https://dx.doi.org/10.1007/s10067-022-06402-w.

@article{2224707,
   author = {Singh, Ambrish and MolinaandGarcia, Pablo and Hussain, Mohammad Salman and Paul, Alok and Das, Siddharth Kumar and YingandYing, Leung and Hill, Catherine L and Danda, Debashish and Samuels, Jonathan and Antony, Benny},
   article_location = {LONDON},
   article_number = {3},
   doi = {http://dx.doi.org/10.1007/s10067-022-06402-w},
   keywords = {Calcium pyrophosphate; Chondrocalcinosis; Colchicine; Osteoarthritis; Osteoarthritis knee},
   language = {eng},
   issn = {0770-3198},
   journal = {Clinical Rheumatology},
   title = {Efficacy and safety of colchicine for the treatment of osteoarthritis: a systematic review and meta-analysis of intervention trials},
   url = {https://link.springer.com/article/10.1007/s10067-022-06402-w},
   volume = {42},
   year = {2023}
}

TY  - JOUR
ID  - 2224707
AU  - Singh, Ambrish - Molina-Garcia, Pablo - Hussain, Mohammad Salman - Paul, Alok - Das, Siddharth Kumar - Ying-Ying, Leung - Hill, Catherine L - Danda, Debashish - Samuels, Jonathan - Antony, Benny
PY  - 2023
TI  - Efficacy and safety of colchicine for the treatment of osteoarthritis: a systematic review and meta-analysis of intervention trials
JF  - Clinical Rheumatology
VL  - 42
IS  - 3
SP  - 889-902
EP  - 889-902
PB  - SPRINGER LONDON LTD
SN  - 07703198
KW  - Calcium pyrophosphate
KW  - Chondrocalcinosis
KW  - Colchicine
KW  - Osteoarthritis
KW  - Osteoarthritis knee
UR  - https://link.springer.com/article/10.1007/s10067-022-06402-w
N2  - Objective Colchicine, an approved treatment for gout, has been trialed in many diseases including osteoarthritis (OA) due to its anti-inflammatory effects. However, its efficacy and safety remain unclear in OA. This systematic review and meta-analysis evaluated the efficacy and safety of colchicine for the treatment of OA. Methods PubMed, Web of Science, Scopus, and Cochrane Central were searched from inception through September 2022. Two reviewers independently screened for randomized controlled trials (RCTs) comparing colchicine with placebo or other active comparators for the treatment of OA (knee, hand, or hip OA), extracted data, and performed Cochrane risk of bias assessments. Result Nine RCTs for the knee OA and one for the hand OA were identified, consisting of 847 patients (429 in colchicine arms, 409 in control arms). The studies were conducted between 2002 and 2021 with follow-up periods ranging from 2 to 12 months, in India, Iran, Turkey, Australia, Singapore, and Iraq. Moderate-quality evidence showed no clinically important pain reduction with colchicine compared to control (standardized mean difference [SMD], 0.17; 95% confidence interval [CI], − 0.55, 0.22). Moderate-quality evidence showed no improvement in function with colchicine compared to control in knee OA patients (SMD, − 0.37; 95% CI, − 0.87, 0.13). Colchicine showed an acceptable safety profile with AEs/SAEs comparable to control. Conclusion Current evidence does not suggest a benefit of colchicine in reducing pain and improving physical function in the overall cohort of hand/knee OA patients. Future trials should focus on the subgroups of OA patients with local or systemic inflammation and/or mineralization who might benefit from colchicine.
ER  -

SINGH, Ambrish, Pablo MOLINA-GARCIA, Mohammad Salman HUSSAIN, Alok PAUL, Siddharth Kumar DAS, Leung YING-YING, Catherine L HILL, Debashish DANDA, Jonathan SAMUELS a Benny ANTONY. Efficacy and safety of colchicine for the treatment of osteoarthritis: a systematic review and meta-analysis of intervention trials. \textit{Clinical Rheumatology}. LONDON: SPRINGER LONDON LTD, 2023, roč.~42, č.~3, s.~889-902. ISSN~0770-3198. Dostupné z: https://dx.doi.org/10.1007/s10067-022-06402-w.

Podrobný výpis o publikaci